JP2013533227A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533227A5
JP2013533227A5 JP2013513645A JP2013513645A JP2013533227A5 JP 2013533227 A5 JP2013533227 A5 JP 2013533227A5 JP 2013513645 A JP2013513645 A JP 2013513645A JP 2013513645 A JP2013513645 A JP 2013513645A JP 2013533227 A5 JP2013533227 A5 JP 2013533227A5
Authority
JP
Japan
Prior art keywords
ethoxy
fgf21
acetylamino
des181
conh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013513645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533227A (ja
Filing date
Publication date
Priority claimed from PCT/EP2010/057986 external-priority patent/WO2010142665A1/en
Application filed filed Critical
Priority claimed from PCT/EP2011/059273 external-priority patent/WO2011154349A2/en
Publication of JP2013533227A publication Critical patent/JP2013533227A/ja
Publication of JP2013533227A5 publication Critical patent/JP2013533227A5/ja
Withdrawn legal-status Critical Current

Links

JP2013513645A 2010-06-08 2011-06-06 Ｆｇｆ２１類似体および誘導体 Withdrawn JP2013533227A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EPPCT/EP2010/057986 2010-06-08
PCT/EP2010/057986 WO2010142665A1 (en) 2009-06-11 2010-06-08 Glp-1 and fgf21 combinations for treatment of diabetes type 2
CN2010001099 2010-07-21
CN2010/001099 2010-07-21
US37329010P 2010-08-13 2010-08-13
US61/373,290 2010-08-13
PCT/EP2011/059273 WO2011154349A2 (en) 2010-06-08 2011-06-06 Fgf21 analogues and derivatives

Publications (2)

Publication Number Publication Date
JP2013533227A JP2013533227A (ja) 2013-08-22
JP2013533227A5 true JP2013533227A5 (enExample) 2014-07-24

Family

ID=49179102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513645A Withdrawn JP2013533227A (ja) 2010-06-08 2011-06-06 Ｆｇｆ２１類似体および誘導体

Country Status (2)

Country Link
JP (1) JP2013533227A (enExample)
WO (1) WO2011154349A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
CN104364261B (zh) * 2012-06-11 2017-04-05 伊莱利利公司 成纤维细胞生长因子21变体
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
WO2015103782A1 (en) * 2014-01-13 2015-07-16 Wenzhou Medical College Biological Pharmaceuticals And Nature Products Ltd., Co Fgf21 mutant and conjugate thereof
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
EP3125921B1 (en) 2014-03-11 2020-07-08 Novartis AG Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016065106A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
HRP20191292T1 (hr) * 2014-12-23 2019-10-18 Novo Nordisk A/S Derivati fgf21 i njihova upotreba
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
EP3442997A2 (en) * 2016-04-15 2019-02-20 Indiana University Research & Technology Corporation Fgf21 c-terminal peptide optimization
CN109789186A (zh) * 2016-05-25 2019-05-21 得克萨斯系统大学评议会 用于治疗分泌性疾病的方法和组合物
WO2017220706A1 (en) 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN108619490A (zh) * 2017-03-22 2018-10-09 天士力医药集团股份有限公司 一种长效化突变的人源成纤维生长因子的新用途
MX2019012331A (es) 2017-04-21 2020-01-23 Yuhan Corp Metodo para producir proteinas de doble funcion y sus derivados.
EP3678686A1 (en) 2017-09-08 2020-07-15 Bristol-Myers Squibb Company Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
CN111601613A (zh) 2017-12-22 2020-08-28 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
AU2019297327A1 (en) 2018-07-03 2021-02-18 Bristol-Myers Squibb Company FGF21 formulations
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
KR20220125289A (ko) 2020-01-08 2022-09-14 브리스톨-마이어스 스큅 컴퍼니 Fgf-21 접합체 제제
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
WO2022238503A1 (en) * 2021-05-11 2022-11-17 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
CN116162145A (zh) 2021-09-08 2023-05-26 北京志道生物科技有限公司 一种fgf21突变蛋白及其应用
CN119343365A (zh) 2022-06-03 2025-01-21 勃林格殷格翰国际有限公司 骨髓源性生长因子的重组表达
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
TW202539726A (zh) 2023-12-06 2025-10-16 德商百靈佳殷格翰國際股份有限公司 包含骨髓衍生性生長因子之新穎調配物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
WO2005091944A2 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
PL1751184T3 (pl) 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
DK1789442T3 (da) 2004-09-02 2009-11-16 Lilly Co Eli Muteiner af fibroblastvækstfaktor 21
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1831371A2 (en) 2004-12-14 2007-09-12 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006078463A2 (en) 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
EA032727B1 (ru) * 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
KR20110117666A (ko) * 2009-01-23 2011-10-27 노보 노르디스크 에이/에스 알부민 바인더 ａ-ｂ-ｃ-ｄ-ｅ-를 갖는 ｆｇｆ21 유도체 및 그것의 사용
US20120172298A1 (en) * 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2

Similar Documents

Publication Publication Date Title
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
JP2013532644A5 (enExample)
JP2017500289A5 (enExample)
JP2012529463A5 (enExample)
HRP20181026T1 (hr) Dugodjelujuće formulacije inzulina
MY174002A (en) Combination theraphy for the treatment of diabetes
UA114700C2 (uk) Тверда фармацевтична форма для перорального застосування та процес її виготовлення
JP2013530974A5 (enExample)
HRP20140480T1 (hr) Pegilirani spojevi inzulina lispro
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
WO2009033770A3 (en) Calcitonin c-terminal flanking peptide for use as a therapeutic agent
WO2009043466A3 (en) Therapeutic use of the peptide gluten exorphin a5
RU2016135543A (ru) Новые производные инсулина и их применение в медицине
WO2009033792A3 (en) Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2009039985A3 (en) Therapeutic uses of urocortin ii
JP2018527288A5 (enExample)
ATE520406T1 (de) Kristalline form des ibandronat-natriums
WO2009046822A3 (en) Use of the peptide ymdgtmsqv as a therapeutic agent
WO2009033712A3 (en) Use of melanotan ii as a therapeutic agent
JP2017508741A5 (enExample)
JP2011046708A5 (enExample)
WO2009046858A3 (en) Therapeutic uses of kisspeptin 13 and compositions thereof
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
JP2011518176A5 (enExample)